Evidence map›Paper›PMID 40290950›Full record

ArticleACS omega2025

Oxidation and Hydrolysis of Ginsenoside Rg5: An Underestimated Degradation Pathway, Isolation, and Characterization of Unknown Degradation Products.

Leqin Cheng, Anqi Ye, Yunqi Tao, Yuewei Zhang

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Leqin ChengSchool of Chemistry and Pharmaceutical Engineering, Jilin Institute of Chemical Technology, Jilin 132022, China.
Anqi YeSchool of Chemistry and Pharmaceutical Engineering, Jilin Institute of Chemical Technology, Jilin 132022, China.
Yunqi TaoSchool of Chemistry and Pharmaceutical Engineering, Jilin Institute of Chemical Technology, Jilin 132022, China.
Yuewei ZhangSchool of Chemistry and Pharmaceutical Engineering, Jilin Institute of Chemical Technology, Jilin 132022, China.ORCID https://orcid.org/0000-0001-6696-0336

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ginsenoside Rg5, a secondary ginsenoside derived from the degradation of protopanaxadiol saponins, exhibits various pharmacological activities, including anticancer, anti-inflammatory, antidiabetic, and memory-enhancing effects, making it a promising candidate for natural medicine. However, research on the stability of Rg5, particularly in aqueous solutions, remains limited. This study systematically investigates the stability of ginsenoside Rg5 in water by monitoring its degradation over time under controlled conditions. The stability of the Rg5 aqueous solution was assessed by investigating the influences of temperature and time, employing high-performance liquid chromatography (HPLC) analysis to evaluate its degradation. The findings indicated substantial degradation of Rg5, with approximately 95% decomposition observed after a period of 10 days. The decomposition products were isolated using preparative liquid chromatography and identified through high-resolution mass spectrometry (HR-MS), NMR, and induced circular dichroism (ICD) analyses. A novel derivative was identified, and its degradation pathway was elucidated, encompassing oxidation, hydrolysis, and dehydration processes that culminated in the formation of four distinct stereoisomers. This study elucidates the instability of Rg5 in aqueous environments and offers significant insights into its decomposition mechanism. The findings emphasize the critical importance of optimizing storage conditions and minimizing exposure to water and oxygen to enhance the stability of Rg5, thereby advancing its potential applications in pharmaceutical development and storage.

Identifiers

PMID40290950
PMCPMC12019737

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.